Related Experiment Video
Updated: Aug 5, 2026

A Macrophage-Tumor Spheroid Co-Invasion Assay
Published on: January 24, 2025
Cross-scale modeling reveals a TFRC-driven immunosuppressive macrophage niche in cervical cancer
Yusha Chen1, Ling Wang2,3, Suyu Li4
1Cervical disease diagnosis and treatment health center, Fujian Maternity and Child Health Hospital College of Clinical Medical for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Background:
The functional plasticity of tumor-associated macrophages (TAMs) is a critical determinant of the immunosuppressive microenvironment in cervical cancer, yet its integration into actionable prognostic frameworks remains limited. This study aimed to establish a TAM polarization-centered model and elucidate the mechanisms of underlying tumor-immune crosstalk.
Methods:
Bulk transcriptomics from The Cancer Genome Atlas (TCGA) were integrated with single-cell RNA sequencing (scRNA-seq) data (GSE208653). By combining weighted gene co-expression network analysis (WGCNA) with a multi-algorithm machine learning framework, a prognostic signature was constructed and independently validated in the Gene Expression Omnibus (GEO) GSE52903 cohort. Single-cell analysis resolved the cellular origins of signature genes, prioritizing tumor-enriched genes for validation. Protein-level expression was verified via immunohistochemistry (IHC) in a paired clinical cohort (n=39). Functional validation of the core gene was performed in vitro using cervical cancer cell lines co-cultured with THP-1-derived macrophages. Polarization was assessed via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), Western blot (WB), enzyme-linked immunosorbent assay (ELISA), flow cytometry, and multiplex immunofluorescence (mIF).
Results:
A robust five-gene prognostic signature (TP73, TFRC, SHC1, SCD, and PFKFB3) was developed, effectively stratifying patient survival. High risk scores correlated with a suppressed antitumor immune landscape and diminished predicted chemosensitivity to agents such as cisplatin. Single-cell analysis and IHC confirmed transferrin receptor (TFRC) as a tumor-intrinsic factor that is progressively upregulated during cervical carcinogenesis and enhances pro-M2 signaling. In vitro co-culture assays demonstrated that tumor-derived TFRC actively orchestrates an immunosuppressive M2-like macrophage niche, driving phenotypic shifts and pro-tumorigenic cytokine secretion, characterized by elevated interleukin-10 (IL-10) and reduced TNF-α. RT-qPCR analysis of 40 clinical specimens further confirmed a significant positive correlation between TFRC and the M2 marker Arg-1 at the mRNA level (r = 0.4961, P = 0.0011).
Conclusions:
This study establishes a cross-scale, biologically interpretable prognostic model linking macrophage plasticity to clinical outcomes. We identify TFRC as a pivotal metabolic-immune node through which tumor-intrinsic iron metabolism orchestrates an immunosuppressive niche, providing a foundation for novel therapeutic strategies in cervical cancer.